JP2009516519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516519A5 JP2009516519A5 JP2008541555A JP2008541555A JP2009516519A5 JP 2009516519 A5 JP2009516519 A5 JP 2009516519A5 JP 2008541555 A JP2008541555 A JP 2008541555A JP 2008541555 A JP2008541555 A JP 2008541555A JP 2009516519 A5 JP2009516519 A5 JP 2009516519A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- formulation
- preparation according
- antigen
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 claims 34
- 238000009472 formulation Methods 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- -1 MUM -1 Proteins 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 239000002270 dispersing agent Substances 0.000 claims 5
- 239000012678 infectious agent Substances 0.000 claims 5
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 4
- 241001631646 Papillomaviridae Species 0.000 claims 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 4
- 241000607768 Shigella Species 0.000 claims 4
- 241000223996 Toxoplasma Species 0.000 claims 4
- 239000012760 heat stabilizer Substances 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- 101800000504 3C-like protease Proteins 0.000 claims 2
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims 2
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims 2
- 102100036464 Activated RNA polymerase II transcriptional coactivator p15 Human genes 0.000 claims 2
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 241000228212 Aspergillus Species 0.000 claims 2
- 241000700663 Avipoxvirus Species 0.000 claims 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 2
- 101150040947 BCY1 gene Proteins 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 241000588807 Bordetella Species 0.000 claims 2
- 241000589968 Borrelia Species 0.000 claims 2
- 241000908522 Borreliella Species 0.000 claims 2
- 102100027305 Box C/D snoRNA protein 1 Human genes 0.000 claims 2
- 241000589562 Brucella Species 0.000 claims 2
- 241000589876 Campylobacter Species 0.000 claims 2
- 241000606161 Chlamydia Species 0.000 claims 2
- 241000606153 Chlamydia trachomatis Species 0.000 claims 2
- 241000193403 Clostridium Species 0.000 claims 2
- 241000193155 Clostridium botulinum Species 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000186216 Corynebacterium Species 0.000 claims 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 2
- 241000725619 Dengue virus Species 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 102100028570 Drebrin-like protein Human genes 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 241001115402 Ebolavirus Species 0.000 claims 2
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 claims 2
- 241000588914 Enterobacter Species 0.000 claims 2
- 241000194033 Enterococcus Species 0.000 claims 2
- 241000991587 Enterovirus C Species 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 241000588722 Escherichia Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102100039717 G antigen 1 Human genes 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 241000606790 Haemophilus Species 0.000 claims 2
- 241000589989 Helicobacter Species 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 208000005331 Hepatitis D Diseases 0.000 claims 2
- 102100023920 Histone H1t Human genes 0.000 claims 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 2
- 101000937756 Homo sapiens Box C/D snoRNA protein 1 Proteins 0.000 claims 2
- 101000915399 Homo sapiens Drebrin-like protein Proteins 0.000 claims 2
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims 2
- 101000905044 Homo sapiens Histone H1t Proteins 0.000 claims 2
- 101001008951 Homo sapiens Kinesin-like protein KIF15 Proteins 0.000 claims 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000831887 Homo sapiens STE20-related kinase adapter protein alpha Proteins 0.000 claims 2
- 101000632529 Homo sapiens Shugoshin 1 Proteins 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 102100027630 Kinesin-like protein KIF15 Human genes 0.000 claims 2
- 102100023426 Kinesin-like protein KIF2A Human genes 0.000 claims 2
- 101710134365 Kinesin-like protein KIF2A Proteins 0.000 claims 2
- 241000588748 Klebsiella Species 0.000 claims 2
- 241000589248 Legionella Species 0.000 claims 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 2
- 241000186781 Listeria Species 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 108010063954 Mucins Proteins 0.000 claims 2
- 241000711386 Mumps virus Species 0.000 claims 2
- 241000186359 Mycobacterium Species 0.000 claims 2
- 241000204031 Mycoplasma Species 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 2
- 241000187654 Nocardia Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000700629 Orthopoxvirus Species 0.000 claims 2
- 241000606860 Pasteurella Species 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 241000711798 Rabies lyssavirus Species 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 241000606701 Rickettsia Species 0.000 claims 2
- 102100024171 STE20-related kinase adapter protein alpha Human genes 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims 2
- 102100028402 Shugoshin 1 Human genes 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 241000243774 Trichinella Species 0.000 claims 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims 2
- 241000223104 Trypanosoma Species 0.000 claims 2
- 102100040418 Tumor protein D52 Human genes 0.000 claims 2
- 101710190247 Tumor protein D52 Proteins 0.000 claims 2
- 102000003425 Tyrosinase Human genes 0.000 claims 2
- 108060008724 Tyrosinase Proteins 0.000 claims 2
- 241000700647 Variola virus Species 0.000 claims 2
- 241000607598 Vibrio Species 0.000 claims 2
- 241000607626 Vibrio cholerae Species 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 claims 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 claims 2
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 206010013023 diphtheria Diseases 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 201000010284 hepatitis E Diseases 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 235000013336 milk Nutrition 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 claims 2
- 101800000607 p15 Proteins 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 229940118696 vibrio cholerae Drugs 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 1
- 241000223203 Coccidioides Species 0.000 claims 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 1
- 241000223935 Cryptosporidium Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 208000000666 Fowlpox Diseases 0.000 claims 1
- 241000224466 Giardia Species 0.000 claims 1
- 241000228402 Histoplasma Species 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 241000224016 Plasmodium Species 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 241000242678 Schistosoma Species 0.000 claims 1
- 241000287219 Serinus canaria Species 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59728005P | 2005-11-21 | 2005-11-21 | |
| US60/597,280 | 2005-11-21 | ||
| PCT/CA2006/001855 WO2007056847A1 (en) | 2005-11-21 | 2006-11-15 | Stabilizing formulations for recombinant viruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516519A JP2009516519A (ja) | 2009-04-23 |
| JP2009516519A5 true JP2009516519A5 (OSRAM) | 2010-03-25 |
| JP5138601B2 JP5138601B2 (ja) | 2013-02-06 |
Family
ID=38048241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541555A Expired - Fee Related JP5138601B2 (ja) | 2005-11-21 | 2006-11-15 | 組換えウイルス安定化製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090169581A1 (OSRAM) |
| EP (1) | EP1951865A4 (OSRAM) |
| JP (1) | JP5138601B2 (OSRAM) |
| KR (1) | KR101357685B1 (OSRAM) |
| CN (2) | CN101360821A (OSRAM) |
| AU (1) | AU2006315026B2 (OSRAM) |
| BR (1) | BRPI0618850A2 (OSRAM) |
| CA (1) | CA2630349A1 (OSRAM) |
| IL (1) | IL191595A (OSRAM) |
| WO (1) | WO2007056847A1 (OSRAM) |
| ZA (1) | ZA200804356B (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2615390T3 (es) | 2008-03-05 | 2017-06-06 | Sanofi Pasteur | Proceso para estabilizar una composición de vacuna que contiene adyuvante |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN101407788B (zh) * | 2008-11-26 | 2012-01-11 | 中国兽医药品监察所 | 一种促进狂犬病病毒增殖的方法 |
| CA2785926A1 (en) * | 2009-12-31 | 2011-07-07 | Mannkind Corporation | Injectable formulations for parenteral administration |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| RS59830B1 (sr) | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| GB2499480A (en) | 2010-03-31 | 2013-08-21 | Stabilitech Ltd | Method for preserving alum adjuvants and alum-adjuvanted vaccines |
| JP5960120B2 (ja) | 2010-03-31 | 2016-08-02 | スタビリテック リミテッド | ウイルス粒子の安定化 |
| JP5869553B2 (ja) | 2010-03-31 | 2016-02-24 | スタビリテック リミテッド | ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤 |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| FR2960781B1 (fr) * | 2010-06-07 | 2013-11-22 | Sanofi Pasteur | Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue |
| GB201016471D0 (en) * | 2010-09-30 | 2010-11-17 | Isis Innovation | Viral vector immunogenic compositions |
| MX346784B (es) | 2010-11-12 | 2017-03-31 | Inovio Pharmaceuticals Inc | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. |
| CN103619349A (zh) * | 2011-05-26 | 2014-03-05 | 葛兰素史密丝克莱恩生物有限公司 | 灭活登革热病毒疫苗 |
| US11060068B2 (en) | 2011-06-28 | 2021-07-13 | Leukocare Ag | Stabilisation method for viruses or bacteria |
| GB201117233D0 (en) | 2011-10-05 | 2011-11-16 | Stabilitech Ltd | Stabilisation of polypeptides |
| MY168959A (en) * | 2012-07-24 | 2019-01-28 | Sanofi Pasteur | Vaccine compositions for the prevention of dengue virus infection |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| TWI690322B (zh) * | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| US9480739B2 (en) * | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| WO2015038755A1 (en) * | 2013-09-13 | 2015-03-19 | Wake Forest University Health Sciences | Methods and compositions for treatment of chlamydial infection and related diseases and disorders |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| EP3087188A1 (en) | 2013-12-23 | 2016-11-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| AR099470A1 (es) * | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| GB201406569D0 (en) | 2014-04-11 | 2014-05-28 | Stabilitech Ltd | Vaccine compositions |
| US10183068B2 (en) | 2014-05-16 | 2019-01-22 | Stc.Unm | Vaccination compositions, methods of making, and methods of use |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| MX2017012389A (es) * | 2015-03-27 | 2018-09-19 | Cadila Healthcare Ltd | Vacuna del virus de la parotiditis recombinante jeryl lynn2. |
| US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
| EP3452081A1 (en) | 2016-05-04 | 2019-03-13 | Transgene SA | Combination therapy with cpg tlr9 ligand |
| TW201825674A (zh) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現雙特異性接合分子的溶瘤病毒 |
| US11166915B2 (en) | 2016-09-16 | 2021-11-09 | Leukocare Ag | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| EP3512496B1 (en) * | 2016-09-16 | 2025-07-30 | Leukocare Ag | A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| EP3562946B1 (en) | 2016-12-28 | 2021-11-24 | Transgene SA | Oncolytic viruses and therapeutic molecules |
| WO2018152237A1 (en) | 2017-02-14 | 2018-08-23 | Inventprise, Llc | Heat stable liquid rotavirus vaccine |
| US11110163B2 (en) | 2017-02-14 | 2021-09-07 | Inventprise, Llc | Heat stable vaccines |
| GB2562241B (en) | 2017-05-08 | 2022-04-06 | Stabilitech Biopharma Ltd | Vaccine compositions |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| AU2018346724B2 (en) | 2017-10-05 | 2025-01-09 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
| WO2019170820A1 (en) | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| CN112041434A (zh) | 2018-04-27 | 2020-12-04 | 克里斯托生物技术股份有限公司 | 用于美容性应用的编码一种或多种美容蛋白的重组核酸 |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3847246A1 (en) | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| EP3875119A4 (en) | 2018-10-30 | 2022-08-31 | The University of Tokyo | ONCOLYTIC VIRUS FOR CANCER THERAPY |
| AU2019393877A1 (en) * | 2018-12-05 | 2021-06-17 | Seres Therapeutics, Inc. | Compositions for stabilizing bacteria and uses thereof |
| CN113453712A (zh) | 2018-12-28 | 2021-09-28 | 特兰斯吉恩股份有限公司 | M2缺陷型痘病毒 |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| JP7810554B2 (ja) | 2019-03-01 | 2026-02-03 | アケロイス バイオファーマ， インコーポレイテッド | 抗原特異的免疫細胞におけるｃｄ１６０機能をモジュレートする方法およびその使用 |
| WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
| CN117664682A (zh) * | 2020-06-15 | 2024-03-08 | 深圳市瑞赛生物技术有限公司 | 即用型维生素标准品及其制备方法、使用方法和贮存稳定剂 |
| CN116322740A (zh) | 2020-07-13 | 2023-06-23 | 特兰斯吉恩股份有限公司 | 免疫抑制的治疗 |
| CN114617972B (zh) * | 2020-12-11 | 2023-12-01 | 康希诺生物股份公司 | 一种药物组合物及其应用 |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| AU2023300419A1 (en) | 2022-07-01 | 2025-01-02 | Transgene | Fusion protein comprising a surfactant-protein-d and a member of the tnfsf |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3429965A (en) * | 1966-08-01 | 1969-02-25 | Sterling Drug Inc | Avian pox virus vaccine and process of preparing same |
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| JPS60193925A (ja) * | 1984-03-13 | 1985-10-02 | Chemo Sero Therapeut Res Inst | 凍結乾燥製剤化ワクチン |
| FR2633518B1 (fr) * | 1988-06-30 | 1991-03-22 | Merieux Inst | Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues |
| EP0872249A4 (en) * | 1995-03-17 | 2001-10-24 | Hisamitsu Pharmaceutical Co | GENE TRANSFER PREPARATION |
| US6616931B1 (en) * | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ES2323991T3 (es) * | 1998-11-16 | 2009-07-28 | Introgen Therapeutics, Inc. | Formulacion de adenovirus para terapia genica. |
| US6689600B1 (en) * | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6225289B1 (en) * | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
| ATE467680T1 (de) * | 2001-10-11 | 2010-05-15 | Merck Sharp & Dohme | Hepatitis-c-virus-impfstoff |
| ATE300954T1 (de) * | 2001-12-10 | 2005-08-15 | Bavarian Nordic As | Poxvirus-enthaltende zusammensetzungen und verfahren zu ihrer herstellung |
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| US10446282B2 (en) * | 2011-12-23 | 2019-10-15 | Ge-Hitachi Nuclear Energy Americas Llc | Methods, systems, and computer program products for generating fast neutron spectra |
-
2006
- 2006-11-15 JP JP2008541555A patent/JP5138601B2/ja not_active Expired - Fee Related
- 2006-11-15 BR BRPI0618850-8A patent/BRPI0618850A2/pt active Search and Examination
- 2006-11-15 CN CNA2006800512997A patent/CN101360821A/zh active Pending
- 2006-11-15 CN CN201510239248.8A patent/CN104984352A/zh active Pending
- 2006-11-15 US US12/094,302 patent/US20090169581A1/en not_active Abandoned
- 2006-11-15 EP EP06804724A patent/EP1951865A4/en not_active Withdrawn
- 2006-11-15 WO PCT/CA2006/001855 patent/WO2007056847A1/en not_active Ceased
- 2006-11-15 CA CA002630349A patent/CA2630349A1/en not_active Abandoned
- 2006-11-15 KR KR1020087014882A patent/KR101357685B1/ko not_active Expired - Fee Related
- 2006-11-15 AU AU2006315026A patent/AU2006315026B2/en not_active Ceased
-
2008
- 2008-05-20 ZA ZA200804356A patent/ZA200804356B/xx unknown
- 2008-05-21 IL IL191595A patent/IL191595A/en not_active IP Right Cessation
-
2015
- 2015-06-02 US US14/728,567 patent/US20150265688A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vajdy et al. | Mucosal adjuvants and delivery systems for protein‐, DNA‐and RNA‐based vaccines | |
| US20230000961A1 (en) | Mesoporous silica compositions comprising inflammatory cytokines for modulating immune responses | |
| Yata et al. | DNA nanotechnology-based composite-type gold nanoparticle-immunostimulatory DNA hydrogel for tumor photothermal immunotherapy | |
| Gregoriadis et al. | A role for liposomes in genetic vaccination | |
| EP1303299B1 (en) | Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens | |
| US8084015B2 (en) | Stabilized synthetic immunogen delivery system | |
| US20150265688A1 (en) | Stabilizing Formulations for Recombinant Viruses | |
| Webster et al. | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | |
| Chen et al. | Non‐viral vector as vaccine carrier | |
| JP2020511114A5 (OSRAM) | ||
| JP2014521687A5 (OSRAM) | ||
| US20070212328A1 (en) | Immunogenic Compositions | |
| JP2003519197A5 (OSRAM) | ||
| Nencioni et al. | Anticancer vaccination strategies | |
| Behzadi et al. | Bacterial toxin's DNA vaccine serves as a strategy for the treatment of cancer, infectious and autoimmune diseases | |
| WO2003050135A2 (en) | Use a parapox b2l protein to modify immune responses to administered antigens | |
| US10232036B2 (en) | Vaccine formulation, preparation method therefor and use thereof | |
| LI et al. | Current status and prospects of mucosal immunity-based vaccine adjuvants and delivery systems for gastrointestinal vaccines | |
| Lin et al. | Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine | |
| Saxena et al. | Contemporary vaccine approaches and role of next-generation vaccine adjuvants in managing viral diseases | |
| HK40024951B (en) | Mesoporous silica compositions for modulating immune responses | |
| HK40024951A (en) | Mesoporous silica compositions for modulating immune responses | |
| Imani Fouladi et al. | Histological analysis antimetastatic effect of intera-venus injection of staphylococcal enterotoxin b and monophosphoryl lipid a against fibrosarchoma in lung tissue | |
| HK1207320B (en) | Mesoporous silica compositions for modulating immune responses |